

5/13/03 mtg

Memorandum of Meeting

Date: May 13, 2003
Place: Harvey W. Wiley Federal Building, College Park, MD
Room 4A023
Subject: Health Claim Petition- California Walnut Commission
(Docket No. 02P-0292)

Participants:

Food and Drug Administration

Center for Food Safety and Applied Nutrition

Office of Nutritional Products, Labeling and Dietary Supplements (ONPLDS)

Christine Taylor, Ph.D., Director (HFS-800)

Joanne Lupton, Ph.D., Visiting Scientist (HFS-800)

Kathleen Ellwood, Ph.D., Director, Division of Nutrition Labeling and Programs
(HFS-830)

James Hoadley, Ph.D., Special Assistant to the Director, Division of Nutrition
Labeling and Programs (HFS-830)

Nancy Crane, M.P.H, R.D., Expert Regulatory Review Scientist, Division of
Nutrition Labeling and Programs (HFS-830)

Office of Science

Elizabeth Yetley, Ph.D., Lead Scientist for Nutrition (HFS-006)

Office of the Commissioner

Office of the Chief Counsel

Gloria Overholser, Esq., Associate Chief Counsel for Foods (GCF-1)

California Walnut Commission

Dennis Balint, Chief Executive Officer, California Walnut Commission

Miriam Guggenheim, Esq., Covington & Burling, Counsel to the California
Walnut Commission

Sarah Taylor, J.D., M.P.H., R.D., Covington & Burling, Counsel to the California
Walnut Commission

Daniel Haley, President, Haley & Associates

Joan Sabaté, M.D., Dr.P.H., Department of Nutrition, Loma Linda University

Artemis Simopoulos, M.D., The Center for Genetics, Nutrition and Health

This meeting was in follow-up to an initial meeting on March 24, 2003 that FDA held with representatives from the California Walnut Commission (CWC) to discuss FDA's tentative conclusions in a letter dated February 25, 2003, in response to a health claim petition submitted on behalf of the CWC. This petition requested FDA to authorize a

02P-0292

MM 2

health claim about the relationship between the consumption of walnuts and reduced risk of coronary heart disease on the label or in the labeling of whole or chopped walnuts.

This second meeting was held to provide CWC representatives the opportunity to share additional information to support their position that walnuts are unique compared to other nuts. FDA and CWC representatives discussed the additional information that was supplied.

The meeting closed with a discussion about next steps. An FDA representative noted that the next meeting which was previously scheduled in May would need to be rescheduled, and that FDA would contact CWC representatives to identify a new date. This next meeting will address, among other things, issues regarding the language for a qualified health claim.

Nancy T. Crane, M.P.H., R.D.

cc: FDA meeting participants